{
    "nct_id": "NCT06463249",
    "official_title": "Scaling up Behavioral Weight Loss Opportunities for Cancer Survivors With Overweight or Obesity in Maryland: A Randomized Trial With Adaptive Interventions (Helpline for Weight Loss)",
    "inclusion_criteria": "* Women and men ages 18 or older\n* Able to complete all study requirements in English\n* Have been previously diagnosed with a malignant solid tumor, completed the required surgical, and/or chemotherapy and/or radiation curative intent therapy at least three months prior to enrollment, and have an anticipated treatment-free life span of 12 months or longer. Chemoprophylaxis with tamoxifen or aromatase inhibitors for breast cancer in women and anti- luteinizing hormone-releasing hormone (LHRH) therapy for prostate cancer in men will be permitted.\n* Have a BMI ≥ 27 kg/m2 (BMI ≥ 25 kg/m2 for Asians) and weight ≤ 400 lbs.\n* Have an email address for regular personal use\n* Have a smartphone for personal use, and are willing to use the phone to read emails and text messages, and use an app\n* Have adequate data plan and cell service to support daily use of weight loss app, receive text messages and to support coaching calls\n* Are willing to record weekly weights\n* Are willing to use a tracking app to log food and exercise daily\n* Are willing to complete coaching calls as planned\n* Are willing to prioritize weight loss efforts by making dietary changes and increasing physical activity\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Received any chemotherapy (unless anti-hormonal therapy) and/or radiation three months or less prior to the proposed program date\n* Women who are breastfeeding, pregnant, or planning pregnancy within the next year\n* self-identification of uncontrolled concurrent medical condition likely to limit compliance with the program as determined by investigators.\n* current involvement in another organized weight loss program\n* current use of medications known to substantially affect body weight, including chronic oral steroids, Tirzepatide (Mounjaro™), and weight loss doses of other glucagon-like peptide 1 (GLP-1) agonists (e.g. Wegovy.)\n* bariatric surgery scheduled within the next 12 months\n* plan to move outside the continental United States in the next 12 months\n* Weight loss or gain of >5.0% of body weight during 2 months prior to screening",
    "miscellaneous_criteria": ""
}